About
NexImmune develops antigen-directed immunotherapies using a proprietary AIM nanoparticle platform that programs T cell responses to treat cancer, autoimmune, and infectious diseases.
Explore NexImmune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.